India RNA Therapeutics Market By Product (Vaccines, Drugs), By Type (mRNA Therapeutics, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotide (ASO) Therapeutics, Others), By Indication (Infectious Diseases, Rare Genetic Diseases/Hereditary Diseases, Other), By End User (Hospitals and Clinics, Research Settings), By Region and Competition, Forecast & Opportunities, 2020-2030F

Market Overview

India RNA Therapeutics Market was valued at USD 48.91 Million in 2024 and is expected to reach USD 70.45 Million by 2030 with a CAGR of 6.23% during the forecast period. The RNA Therapeutics Market in India is gaining momentum, driven by advancements in biotechnology, increasing prevalence of genetic and chronic diseases, and the success of mRNA vaccines during the COVID-19 pandemic. With India’s growing focus on personalized medicine, RNA therapeutics are emerging as promising solutions for conditions like cancer, cardiovascular diseases, and rare genetic disorders. The market benefits from significant R&D investments by biopharma companies, a supportive regulatory environment, and cost-effective manufacturing capabilities, particularly in regions like Maharashtra and Gujarat, which serve as biotech and pharmaceutical hubs. Additionally, collaborations between Indian firms and global players are accelerating innovation and commercialization, enabling the introduction of cutting-edge RNA-based treatments.

However, the market also faces challenges such as high development costs, limited local expertise in advanced RNA technologies, and infrastructure gaps in smaller cities. Ensuring the affordability and accessibility of RNA therapeutics for the vast Indian population remains a critical hurdle. Moreover, competition from traditional therapies and the complex regulatory framework for novel biologics can delay market entry. Despite these challenges, the rising demand for precision medicine, coupled with India’s robust pharmaceutical manufacturing landscape, positions the RNA therapeutics market for significant growth in the coming years.

Key Market Drivers

Growing Prevalence of Genetic and Chronic Diseases

The increasing prevalence of genetic and chronic diseases in India is a key driver for the RNA Therapeutics Market. Genetic disorders, such as rare diseases, congenital malformations, and enzyme deficiencies, pose significant challenges to India’s healthcare system, necessitating advanced therapeutic solutions like RNA-based treatments. The substantial burden of rare and inherited diseases highlights the need for personalized medicine, particularly as traditional treatment approaches fail to address the underlying genetic causes effectively. Approximately 70 million individuals in India are affected by known rare diseases, accounting for about one-fifth of the global rare disease population. Moreover, annually, around 500,000 infants are born with congenital malformations, 400,000 with glucose-6-phosphate dehydrogenase (G6PD) deficiency, and 10,000 with amino acid disorders in India.

Chronic diseases further exacerbate India’s healthcare challenges, driving demand for innovative treatments. Cardiovascular diseases (CVDs) remain a leading cause of mortality, with India facing a higher CVD burden than the global average. Similarly, the rapid rise in diabetes prevalence emphasizes the urgent need for advanced therapeutics to manage and mitigate disease progression. RNA therapeutics offer significant promise in tackling such chronic conditions by targeting disease pathways more precisely than conventional therapies. The age-standardized CVD death rate in India is 272 per 100,000 population, significantly higher than the global average of 235 per 100,000 population. Moreover, according to the ICMR INDIAB study (2023), the prevalence of diabetes in India has reached 10.1 crores, placing immense pressure on the healthcare system.

This growing burden of genetic and chronic diseases underscores the critical need for RNA-based therapeutics, which can revolutionize the treatment landscape by offering targeted, efficient, and personalized solutions.

Rising Government and Private Sector Investments

The RNA Therapeutics Market in India is witnessing robust growth, fueled by increasing investments from both the government and the private sector. The Indian government has been actively promoting biotechnology and innovation through initiatives such as the Biotechnology Industry Research Assistance Council (BIRAC) and various grants to encourage research and development in RNA-based therapies. These efforts are aimed at fostering self-reliance in healthcare and reducing dependency on imported advanced therapeutics. Additionally, private players, including leading pharmaceutical and biotech companies, are investing heavily in infrastructure, R&D, and collaborations with global firms to develop RNA vaccines and therapeutics for various diseases, such as cancer and infectious conditions. The establishment of advanced manufacturing facilities and research labs, often supported by state incentives, is further accelerating the adoption and commercialization of RNA therapeutics. These combined efforts from the government and private sector are positioning India as a key player in the global RNA therapeutics landscape.

Simultaneously, private sector investments are intensifying, with major pharmaceutical and biotech companies allocating substantial resources to RNA therapeutics. These firms are establishing state-of-the-art R&D facilities, forging collaborations with international organizations, and focusing on advanced RNA technologies like mRNA vaccines, RNA interference (RNAi), and antisense oligonucleotides (ASOs). This growing interest is further supported by state governments offering incentives to attract biotech ventures, creating clusters of innovation in regions like Maharashtra, Gujarat, and Karnataka. Additionally, venture capital funding and partnerships with global RNA leaders have accelerated research and manufacturing capabilities, enabling India to emerge as a competitive player in the global market.

Together, these government and private sector efforts are not only driving the growth of the RNA therapeutics market but also fostering innovation and improving accessibility to advanced therapies, ultimately enhancing the country’s healthcare infrastructure.

The synergy between government initiatives and private sector investments is fostering a thriving environment for the RNA therapeutics market in India. The government has also focused on building public-private partnerships (PPPs) to bridge the gap between research and commercialization. By providing grants, tax incentives, and subsidies for biotech startups and established firms, the government is encouraging the development of RNA-based solutions for diseases with unmet medical needs. For instance, national programs aimed at tackling rare diseases and genetic disorders align with the broader objective of driving innovation in RNA-based diagnostics and therapeutics. Moreover, the establishment of biotech parks and innovation clusters in states such as Telangana, Karnataka, and Tamil Nadu has created hubs for collaboration and knowledge sharing, further accelerating research breakthroughs in RNA technologies.

On the private front, Indian pharmaceutical giants are increasingly venturing into RNA therapeutics as they recognize its transformative potential. Companies are collaborating with global biotech firms to acquire advanced technologies and expertise, facilitating the production of high-quality RNA vaccines and therapeutics at competitive costs. The COVID-19 pandemic underscored the importance of RNA technology, leading to an influx of funding from venture capital firms and investors who see the potential for long-term growth. Startups and academic institutions are also actively participating, contributing to the development of a robust pipeline of RNA-based drugs targeting conditions like cancer, infectious diseases, and genetic disorders.

Download Free Sample Report

Key Market Challenges

Regulatory and Clinical Challenges

One of the significant challenges facing the RNA therapeutics market in India is the complex regulatory framework and the stringent requirements for clinical trials. Developing RNA-based therapies, such as mRNA vaccines, RNA interference (RNAi) therapeutics, and antisense oligonucleotides (ASOs), involves navigating a multi-layered approval process that can delay product development and commercialization. The lack of specific guidelines tailored to RNA therapeutics in India’s regulatory system adds an extra layer of complexity. Unlike traditional drugs, RNA-based therapies often have unique mechanisms of action and require innovative delivery systems, which may not align well with existing regulatory pathways.

Moreover, conducting large-scale clinical trials in India poses challenges due to the diversity of the population, logistical constraints, and the need for specialized infrastructure. RNA therapeutics are still a relatively new field, and ensuring compliance with global standards for safety, efficacy, and manufacturing quality can be resource-intensive for companies. The cost of clinical trials, combined with the need for advanced research facilities and skilled professionals, further complicates the market landscape. Additionally, the evolving nature of RNA technology means companies must continuously adapt to changing international guidelines, which can strain smaller biotech firms or startups with limited resources.

These regulatory and clinical hurdles create bottlenecks in bringing innovative RNA therapies to market, slowing down the growth potential of the industry. Addressing these challenges will require collaboration between regulatory authorities, industry players, and academic institutions to establish clear, streamlined, and supportive frameworks for RNA-based therapeutics in India.

Key Market Trends

Advancements in Biotechnology and Genomics

The rapid advancements in biotechnology and genomics are shaping the RNA therapeutics market in India, positioning it at the forefront of modern healthcare innovation. Breakthroughs in genomic research have significantly enhanced the understanding of gene expression, disease pathways, and molecular mechanisms, paving the way for targeted RNA-based solutions. The integration of cutting-edge technologies such as next-generation sequencing (NGS), CRISPR-Cas9 gene editing, and synthetic biology has accelerated the development of RNA therapeutics, enabling researchers to identify and address genetic mutations and molecular targets more effectively.

In particular, the advancements in mRNA technology, which came to prominence during the COVID-19 pandemic, have highlighted the potential of RNA therapeutics to revolutionize the treatment of various diseases, including rare genetic disorders, cancers, and chronic illnesses. With the decreasing costs of sequencing technologies and the growing accessibility of genomic data, researchers and companies in India are increasingly focusing on developing RNA-based therapies tailored to the genetic profiles of Indian patients.

Furthermore, biotechnological innovations are driving improvements in RNA delivery systems, such as lipid nanoparticles and polymer-based carriers, ensuring higher stability, precision, and efficacy of RNA therapeutics. These advancements are supported by India's growing bioinformatics capabilities, which leverage artificial intelligence and machine learning to analyze large genomic datasets, optimize therapeutic design, and predict treatment outcomes.

As a result, the convergence of biotechnology and genomics is not only expanding the possibilities for RNA therapeutics but also creating new opportunities for collaborations, research funding, and commercialization in India. This trend is set to transform the healthcare landscape by enabling personalized medicine and addressing unmet medical needs with unparalleled precision and efficiency.

Segmental Insights

Type Insights

Based on Type, mRNA Therapeutics have emerged as the fastest growing segment in the India RNA Therapeutics Market in 2024. This is due to its transformative potential, versatility, and wide-ranging applications. The success of mRNA vaccines, particularly during the COVID-19 pandemic, has underscored the technology's ability to deliver rapid, effective, and scalable solutions for global health challenges. This has not only accelerated interest and investments in mRNA research but also validated its potential to address a variety of diseases beyond infectious ones, such as cancer, rare genetic disorders, and autoimmune conditions.

A key factor driving the growth of mRNA therapeutics is its relatively straightforward and cost-effective manufacturing process compared to traditional biologics. Unlike other RNA-based technologies, mRNA therapeutics can be synthesized in a laboratory without the need for complex cell cultures, enabling faster development timelines. Additionally, advancements in delivery systems, such as lipid nanoparticles, have significantly improved the stability and efficacy of mRNA-based drugs, making them more commercially viable.

India's growing focus on biotechnology and personalized medicine further boosts the adoption of mRNA therapeutics. Researchers and biotech firms in the country are exploring mRNA's potential to address unmet medical needs, particularly in oncology and rare diseases, where conventional therapies have limitations. The flexibility of mRNA to encode various proteins also makes it a powerful platform for developing treatments for a broad spectrum of conditions.

Product Insights

Based on Indication, Infectious Diseases have emerged as the dominating segment in the India RNA Therapeutics Market in 2024, primarily driven by the success of RNA-based vaccines and therapeutics. The COVID-19 pandemic showcased the potential of RNA technology in combating infectious diseases, leading to increased investments and research in this field. India, with its vast population and high disease burden, faces ongoing challenges from conditions such as tuberculosis, hepatitis, and influenza, which further fuel the demand for RNA-based solutions.

Government initiatives promoting biotechnology advancements and public-private partnerships have played a crucial role in accelerating the adoption of RNA therapeutics. Research institutions and pharmaceutical companies are focusing on improving RNA delivery mechanisms, enhancing stability, and reducing costs, making these therapies more accessible. Moreover, increasing awareness among healthcare professionals and patients regarding the benefits of RNA-based treatments, such as their ability to provide targeted and rapid responses, is contributing to market growth.

Advancements in next-generation sequencing, bioinformatics, and nanotechnology are further supporting the expansion of this segment. As India continues to strengthen its healthcare infrastructure and regulatory frameworks, the RNA therapeutics market is expected to witness sustained growth, with infectious diseases remaining at the forefront of innovation and development.

Download Free Sample Report

Regional Insights

Based on Region, West India have emerged as the dominating region in the India RNA Therapeutics Market in 2024. West India is emerging as a dominant region in the RNA therapeutics market due to its robust biotechnology and pharmaceutical ecosystem, world-class infrastructure, and supportive government policies. States like Maharashtra and Gujarat are home to some of the largest pharmaceutical hubs in India, with cities like Pune, Mumbai, and Ahmedabad leading in research, manufacturing, and innovation. The presence of established pharmaceutical giants, biotech startups, and research institutions in these areas creates a fertile ground for the development and commercialization of advanced RNA therapeutics.

Additionally, West India benefits from a well-developed infrastructure for pharmaceutical manufacturing and exports. Gujarat, in particular, accounts for a significant share of India's pharmaceutical exports and houses advanced facilities for biologics and RNA-based drug production. The region's proximity to major ports further strengthens its export capabilities, enabling faster delivery of RNA-based products to global markets.

Recent Development

• In September 2024, Aurora Biosynthetics, a cutting-edge biotech firm, has launched with a mission to transform RNA therapeutics manufacturing. By leveraging advanced bioengineering technologies, the company aims to streamline production processes, enhance scalability, and reduce costs. Aurora’s innovative approach is set to address global demand for mRNA therapies, targeting applications in infectious diseases, oncology, and rare genetic disorders.
• In September 2024, Cytiva has launched an advanced RNA delivery LNP (Lipid Nanoparticle) kit for its NanoAssemblr Ignite platform in India. This cutting-edge kit enables precise and efficient encapsulation of RNA molecules for therapeutics and vaccine development. Designed to streamline research and manufacturing, the kit supports the growing demand for RNA-based innovations in India, empowering biotech companies and research institutions with enhanced RNA delivery solutions.
• In July 2024, Biostate AI has launched two innovative tools in India: Total RNA Sequencing and OmicsWeb Copilot for RNA sequence data analysis. Total RNA Sequencing offers comprehensive insights into gene expression, while OmicsWeb Copilot simplifies RNA data analysis using advanced AI algorithms. These tools aim to accelerate RNA research and precision medicine, empowering researchers with efficient and accurate solutions.
• In September 2023, Spain-based Insud Pharma has inaugurated a state-of-the-art Oligonucleotides Centre in Hyderabad, India, marking its first facility of this kind in the country. This advanced center focuses on the development and manufacturing of oligonucleotide-based therapeutics, critical for addressing genetic and rare diseases. With cutting-edge technology and a skilled workforce, the facility aims to enhance India's RNA therapeutics landscape while supporting global demand for precision medicine.

Key Market Players

• Pfizer Limited
• Novartis AG
• Sanofi S.A.
• Biocon Ltd Company
• Gennova Biopharmaceuticals Ltd.
• Cipla Limited
• Dr. Reddy's Laboratories
• Sun Pharmaceutical Industries Ltd.
• Bharat Biotech
• Serum Institute of India

Report Scope

In this report, the India RNA Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• India RNA Therapeutics Market, By Product:

o   Vaccines

o   Drugs

• India RNA Therapeutics Market, By Type:

o   mRNA Therapeutics

o   RNA Interference (RNAi) Therapeutics

o   Antisense Oligonucleotide (ASO) Therapeutics

o   Others

• India RNA Therapeutics Market, By Indication:

o   Infectious Diseases

o   Rare Genetic Diseases/Hereditary Diseases

o   Other

• India RNA Therapeutics Market, By End User:

o   Hospitals and Clinics

o   Research Settings

• India RNA Therapeutics Market, By Region:

o   East India

o   West India

o   North India

o   South India

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the India RNA Therapeutics Market.

Available Customizations:

India RNA Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

India RNA Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com